FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306404805> ?p ?o ?g. }

• W4306404805 endingPage "S1395" @default.
• W4306404805 startingPage "S1395" @default.
• W4306404805 abstract "BackgroundCisplatin is used as first-line chemotherapy treatment for patients diagnosed with various types of malignancies, such as leukemia, lymphomas, breast, testicular, ovarian, head and neck, non-small lung, cervical cancers, and sarcomas. However, our recent study provided evince on the activation of DNA repair genes in p53 wild-type of breast, non-small lung and liver cancer, but not in mutated triple-negative breast cancer or p53 deficient myeloid leukemia.MethodsRNA- and ChIP-Seq, cellular technics (toxicity, confocal immunostaining, western blot, real-time PCR) we found p53 wild-type interaction with EP300 at the promoters of PARP1, BRCA1 and RAD51.ResultsRNA-Seq data confirmed that pharmacological inhibition of ATM/ATR, EP300 and transient silencing of p53 prevent overexpression of genes contributing to nucleotide excision repair (GO:0006289), double-strand break repair via homologous recombination (GO:0000724) and nonhomologous end joining (GO:0006303) and DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest (GO:0006977). This was not observed in p53 single-nucleotide or deletion mutants. Since transcription of majority of genes involved in DNA repair is controlled by cell cycle progression via E2F activity, we paid attention to p53 interaction with chromatin upon cisplatin treatment. ChIP-Seq data confirmed the enrichment of approximately 1200 genomic locations, where only 7% overlapped with E2F1, but 22% with EP300 peaks. Prediction of target genes linked p53 enriched regions with genes assigned to nucleotide-excision repair and DNA damage recognition (GO:0000715). Cisplatin caused p53 co-localization with EP300 in the nuclei, but E2F1 silencing restrained the enrichment of both proteins on chromatin. Pharmacological inhibition of ATR/ATM, EP300 and p53 silencing considerably increased cisplatin cytotoxicity. The same effect of EP300 inhibitors on cisplatin cytotoxicity was observed in cisplatin-resistant p53 wild-type breast and non-small lung cancers.ConclusionsATM/ATR-p53/E2F1/EP300 pathway allows cells to increase resistance to cisplatin. Addition of EP300 inhibitors may improve cisplatin-based chemotherapies of p53 wild-type cancers and improve chemotherapy outcome.Legal entity responsible for the studyThe authors.FundingNational Center for Research and Development (LIDER/22/0122/L-10/18/NCBR/2019) and Ministry of Education and Science (IDUB-60/2021).DisclosureAll authors have declared no conflicts of interest. BackgroundCisplatin is used as first-line chemotherapy treatment for patients diagnosed with various types of malignancies, such as leukemia, lymphomas, breast, testicular, ovarian, head and neck, non-small lung, cervical cancers, and sarcomas. However, our recent study provided evince on the activation of DNA repair genes in p53 wild-type of breast, non-small lung and liver cancer, but not in mutated triple-negative breast cancer or p53 deficient myeloid leukemia. Cisplatin is used as first-line chemotherapy treatment for patients diagnosed with various types of malignancies, such as leukemia, lymphomas, breast, testicular, ovarian, head and neck, non-small lung, cervical cancers, and sarcomas. However, our recent study provided evince on the activation of DNA repair genes in p53 wild-type of breast, non-small lung and liver cancer, but not in mutated triple-negative breast cancer or p53 deficient myeloid leukemia. MethodsRNA- and ChIP-Seq, cellular technics (toxicity, confocal immunostaining, western blot, real-time PCR) we found p53 wild-type interaction with EP300 at the promoters of PARP1, BRCA1 and RAD51. RNA- and ChIP-Seq, cellular technics (toxicity, confocal immunostaining, western blot, real-time PCR) we found p53 wild-type interaction with EP300 at the promoters of PARP1, BRCA1 and RAD51. ResultsRNA-Seq data confirmed that pharmacological inhibition of ATM/ATR, EP300 and transient silencing of p53 prevent overexpression of genes contributing to nucleotide excision repair (GO:0006289), double-strand break repair via homologous recombination (GO:0000724) and nonhomologous end joining (GO:0006303) and DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest (GO:0006977). This was not observed in p53 single-nucleotide or deletion mutants. Since transcription of majority of genes involved in DNA repair is controlled by cell cycle progression via E2F activity, we paid attention to p53 interaction with chromatin upon cisplatin treatment. ChIP-Seq data confirmed the enrichment of approximately 1200 genomic locations, where only 7% overlapped with E2F1, but 22% with EP300 peaks. Prediction of target genes linked p53 enriched regions with genes assigned to nucleotide-excision repair and DNA damage recognition (GO:0000715). Cisplatin caused p53 co-localization with EP300 in the nuclei, but E2F1 silencing restrained the enrichment of both proteins on chromatin. Pharmacological inhibition of ATR/ATM, EP300 and p53 silencing considerably increased cisplatin cytotoxicity. The same effect of EP300 inhibitors on cisplatin cytotoxicity was observed in cisplatin-resistant p53 wild-type breast and non-small lung cancers. RNA-Seq data confirmed that pharmacological inhibition of ATM/ATR, EP300 and transient silencing of p53 prevent overexpression of genes contributing to nucleotide excision repair (GO:0006289), double-strand break repair via homologous recombination (GO:0000724) and nonhomologous end joining (GO:0006303) and DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest (GO:0006977). This was not observed in p53 single-nucleotide or deletion mutants. Since transcription of majority of genes involved in DNA repair is controlled by cell cycle progression via E2F activity, we paid attention to p53 interaction with chromatin upon cisplatin treatment. ChIP-Seq data confirmed the enrichment of approximately 1200 genomic locations, where only 7% overlapped with E2F1, but 22% with EP300 peaks. Prediction of target genes linked p53 enriched regions with genes assigned to nucleotide-excision repair and DNA damage recognition (GO:0000715). Cisplatin caused p53 co-localization with EP300 in the nuclei, but E2F1 silencing restrained the enrichment of both proteins on chromatin. Pharmacological inhibition of ATR/ATM, EP300 and p53 silencing considerably increased cisplatin cytotoxicity. The same effect of EP300 inhibitors on cisplatin cytotoxicity was observed in cisplatin-resistant p53 wild-type breast and non-small lung cancers. ConclusionsATM/ATR-p53/E2F1/EP300 pathway allows cells to increase resistance to cisplatin. Addition of EP300 inhibitors may improve cisplatin-based chemotherapies of p53 wild-type cancers and improve chemotherapy outcome. ATM/ATR-p53/E2F1/EP300 pathway allows cells to increase resistance to cisplatin. Addition of EP300 inhibitors may improve cisplatin-based chemotherapies of p53 wild-type cancers and improve chemotherapy outcome." @default.
• W4306404805 created "2022-10-17" @default.
• W4306404805 creator A5054991587 @default.
• W4306404805 creator A5056035112 @default.
• W4306404805 date "2022-10-01" @default.
• W4306404805 modified "2023-10-09" @default.
• W4306404805 title "36P EP300 as an epigenetic target in p53 wild-type tumors treated with cisplatin" @default.
• W4306404805 doi "https://doi.org/10.1016/j.annonc.2022.09.037" @default.
• W4306404805 hasPublicationYear "2022" @default.
• W4306404805 type Work @default.
• W4306404805 citedByCount "0" @default.
• W4306404805 crossrefType "journal-article" @default.
• W4306404805 hasAuthorship W4306404805A5054991587 @default.
• W4306404805 hasAuthorship W4306404805A5056035112 @default.
• W4306404805 hasBestOaLocation W43064048051 @default.
• W4306404805 hasConcept C104317684 @default.
• W4306404805 hasConcept C104451858 @default.
• W4306404805 hasConcept C134935766 @default.
• W4306404805 hasConcept C143425029 @default.
• W4306404805 hasConcept C153911025 @default.
• W4306404805 hasConcept C182979987 @default.
• W4306404805 hasConcept C2775984157 @default.
• W4306404805 hasConcept C2778480876 @default.
• W4306404805 hasConcept C2779012473 @default.
• W4306404805 hasConcept C502942594 @default.
• W4306404805 hasConcept C54355233 @default.
• W4306404805 hasConcept C552990157 @default.
• W4306404805 hasConcept C82381507 @default.
• W4306404805 hasConcept C86339819 @default.
• W4306404805 hasConcept C86803240 @default.
• W4306404805 hasConcept C94966510 @default.
• W4306404805 hasConceptScore W4306404805C104317684 @default.
• W4306404805 hasConceptScore W4306404805C104451858 @default.
• W4306404805 hasConceptScore W4306404805C134935766 @default.
• W4306404805 hasConceptScore W4306404805C143425029 @default.
• W4306404805 hasConceptScore W4306404805C153911025 @default.
• W4306404805 hasConceptScore W4306404805C182979987 @default.
• W4306404805 hasConceptScore W4306404805C2775984157 @default.
• W4306404805 hasConceptScore W4306404805C2778480876 @default.
• W4306404805 hasConceptScore W4306404805C2779012473 @default.
• W4306404805 hasConceptScore W4306404805C502942594 @default.
• W4306404805 hasConceptScore W4306404805C54355233 @default.
• W4306404805 hasConceptScore W4306404805C552990157 @default.
• W4306404805 hasConceptScore W4306404805C82381507 @default.
• W4306404805 hasConceptScore W4306404805C86339819 @default.
• W4306404805 hasConceptScore W4306404805C86803240 @default.
• W4306404805 hasConceptScore W4306404805C94966510 @default.
• W4306404805 hasLocation W43064048051 @default.
• W4306404805 hasOpenAccess W4306404805 @default.
• W4306404805 hasPrimaryLocation W43064048051 @default.
• W4306404805 hasRelatedWork W1965514945 @default.
• W4306404805 hasRelatedWork W1977382129 @default.
• W4306404805 hasRelatedWork W2004947378 @default.
• W4306404805 hasRelatedWork W2025388536 @default.
• W4306404805 hasRelatedWork W2037260870 @default.
• W4306404805 hasRelatedWork W2102655424 @default.
• W4306404805 hasRelatedWork W2170454539 @default.
• W4306404805 hasRelatedWork W2512850011 @default.
• W4306404805 hasRelatedWork W3122750612 @default.
• W4306404805 hasRelatedWork W4211191096 @default.
• W4306404805 hasVolume "33" @default.
• W4306404805 isParatext "false" @default.
• W4306404805 isRetracted "false" @default.
• W4306404805 workType "article" @default.